167 related articles for article (PubMed ID: 1511432)
1. Comparative antitumor effects of hormonal ablation, estrogen agonist, estrogen cytotoxic derivative, and antiestrogen in the PAIII rat prostatic adenocarcinoma.
Neubauer BL; Best KL; Goode RL; Heiman ML; Hoover DM; Robertson DW; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Cancer Res; 1992 Sep; 52(17):4663-71. PubMed ID: 1511432
[TBL] [Abstract][Full Text] [Related]
2. The selective estrogen receptor modulator trioxifene (LY133314) inhibits metastasis and extends survival in the PAIII rat prostatic carcinoma model.
Neubauer BL; McNulty AM; Chedid M; Chen K; Goode RL; Johnson MA; Jones CD; Krishnan V; Lynch R; Osborne HE; Graff JR
Cancer Res; 2003 Sep; 63(18):6056-62. PubMed ID: 14522935
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
Neubauer BL; Best KL; Counts DF; Goode RL; Hoover DM; Jones CD; Sarosdy MF; Shaar CJ; Tanzer LR; Merriman RL
Prostate; 1995 Oct; 27(4):220-9. PubMed ID: 7479389
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of PAIII rat prostatic adenocarcinoma growth and metastasis by a new diarylsulfonylurea antitumor agent, LY181984.
Neubauer BL; Merriman RL; Best KL; Goode RL; Sarosdy MF; Tanzer LR; Howbert JJ
J Urol; 1992 Feb; 147(2):500-4. PubMed ID: 1732631
[TBL] [Abstract][Full Text] [Related]
5. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555).
George DJ; Dionne CA; Jani J; Angeles T; Murakata C; Lamb J; Isaacs JT
Cancer Res; 1999 May; 59(10):2395-401. PubMed ID: 10344749
[TBL] [Abstract][Full Text] [Related]
6. Metastatic spread of the PAIII prostatic adenocarcinoma after implantation in the tail of the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Merriman RL; Smith GF; Tanzer LR; Hoover DM
Prostate; 1986; 8(3):265-76. PubMed ID: 3703746
[TBL] [Abstract][Full Text] [Related]
7. Effect of coumarin on the normal rat prostate and on the R-3327H prostatic adenocarcinoma.
Omarbasha B; Fair WR; Heston WD
Cancer Res; 1989 Jun; 49(11):3045-9. PubMed ID: 2720665
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the uterotropic activity of estrogens and antiestrogens by the short acting antiestrogen LY117018.
Jordan VC; Gosden B
Endocrinology; 1983 Aug; 113(2):463-8. PubMed ID: 6872937
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects and mechanisms of castration, estrogen anti-androgen, and anti-estrogen-induced regression of accessory sex organ epithelium and muscle.
Neubauer B; Blume C; Cricco R; Greiner J; Mawhinney M
Invest Urol; 1981 Jan; 18(4):229-34. PubMed ID: 7451082
[TBL] [Abstract][Full Text] [Related]
10. Sensitive detection of the endocrine effects of the estrogen analogue ethinylestradiol using a modified enhanced subacute rat study protocol (OECD Test Guideline no. 407).
Andrews P; Freyberger A; Hartmann E; Eiben R; Loof I; Schmidt U; Temerowski M; Folkerts A; Stahl B; Kayser M
Arch Toxicol; 2002 May; 76(4):194-202. PubMed ID: 12029382
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of warfarin on the metastasis of the PAIII prostatic adenocarcinoma in the rat.
Neubauer BL; Bemis KG; Best KL; Goode RL; Hoover DM; Smith GF; Tanzer LR; Merriman RL
J Urol; 1986 Jan; 135(1):163-6. PubMed ID: 3941458
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative and antimetastatic effects of gossypol on Dunning prostate cell-bearing Copenhagen rats.
Chang CJ; Ghosh PK; Hu YF; Brueggemeier RW; Lin YC
Res Commun Chem Pathol Pharmacol; 1993 Mar; 79(3):293-312. PubMed ID: 8480076
[TBL] [Abstract][Full Text] [Related]
13. Antitumor efficacy in rats of CGP 19984, a thiazolidinedione derivative that inhibits luteinizing hormone secretion.
Ip MM; Sylvester PW; Schenkel L
Cancer Res; 1986 Apr; 46(4 Pt 1):1735-40. PubMed ID: 3948162
[TBL] [Abstract][Full Text] [Related]
14. On the effects of oestrogen in the male. Some effects of different oestrogenic substances in rats and men with prostatic carcinoma.
Daehlin L
Scand J Urol Nephrol Suppl; 1985; 91():1-44. PubMed ID: 3868029
[TBL] [Abstract][Full Text] [Related]
15. Functionality of estrogen receptor and tamoxifen treatment of R3327 Dunning rat prostate adenocarcinoma.
Ip MM; Milholland RJ; Rosen F
Cancer Res; 1980 Jul; 40(7):2188-93. PubMed ID: 7388787
[TBL] [Abstract][Full Text] [Related]
16. Effects of 17 beta-estradiol and medroxyprogesterone acetate upon MtTW15 mammosomatotropic pituitary tumor growth and hormone production in male and female rats.
Winneker RC; Parsons JA
Cancer Res; 1981 May; 41(5):1772-7. PubMed ID: 7214344
[TBL] [Abstract][Full Text] [Related]
17. Effect of feed restriction on Hershberger and pubertal male assay endpoints.
Marty MS; Johnson KA; Carney EW
Birth Defects Res B Dev Reprod Toxicol; 2003 Aug; 68(4):363-74. PubMed ID: 14666999
[TBL] [Abstract][Full Text] [Related]
18. In vitro bioeffects of the antiestrogen LY117018 on desmoid tumor and colon cancer cells.
Picariello L; Fiorelli G; Benvenuti S; Brandi ML; Galli G; Malentacchi C; Montali E; Bigozzi U; Ficari F; Tonelli F
Anticancer Res; 1997; 17(3C):2099-104. PubMed ID: 9216671
[TBL] [Abstract][Full Text] [Related]
19. Effect of estracyt on the rat prostate.
Yamanaka H; Shimazaki J; Imai K; Sugiyama Y; Shida K
Invest Urol; 1977 Mar; 14(5):400-4. PubMed ID: 845006
[TBL] [Abstract][Full Text] [Related]
20. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers.
Ichikawa T; Lamb JC; Christensson PI; Hartley-Asp B; Isaacs JT
Cancer Res; 1992 Jun; 52(11):3022-8. PubMed ID: 1591718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
